Department of Veterans Affairs Awarded a Contract to DERMAVANT SCIENCES INC for $5,066,433.25

Summary of Award

The detailed contract data from usaspending.gov provides a comprehensive perspective into a Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Dermavant Sciences Inc. This contract primarily concerns the supply of drugs, pharmaceuticals, and hematology-related products, emphasizing the government's ongoing commitment to supporting veterans' healthcare needs through strategic partnerships with pharmaceutical manufacturers.

The contract, identified by the Award ID #36F79723D0050, was initiated on January 6, 2023, as an Indefinite Delivery Vehicle (IDV) contract characterized as a Fixed-Price with Economic Price Adjustment. This type of pricing is instrumental in managing costs effectively while allowing adjustments related to economic factors over the firm tenure, which spans five years, from January 15, 2023, to January 14, 2028.

Dermavant Sciences Inc., based in Long Beach, California, is the contract recipient responsible for providing pharmaceuticals under this agreement. The company, identified with a unique entity identifier QW21DM7H5714, does not fall under any small business category, indicating it operates at a larger scale, which is not uncommon for pharmaceutical manufacturers. As a U.S.-owned business that is a corporate entity not tax-exempt, Dermavant plays a critical role in manufacturing pharmaceutical preparations, as described under the North American Industry Classification System (NAICS) code 325412. The contract, as stipulated by the VA, is part of a larger pharmaceutical and biologicals supply effort, classified under the Product or Service Code (PSC) 6505. This classification underscores the significance of the associated products in medical supply chains, particularly those directed at addressing the needs of veterans. A noteworthy aspect of the contract lies in its competitive nature. The contract was awarded through full and open competition, as indicated by the "extent competed description" field. The solicitation process, categorized as a "Negotiated Proposal/Quote," signifies that a comprehensive evaluation of proposals occurred before selecting Dermavant Sciences Inc. Given the competitive landscape, the fact that 999 offers were received highlights the contract's appeal within the pharmaceutical industry and the considerable value the government places on cost-effective healthcare solutions. Despite the large ceiling price of $5,066,433.25, the total obligation at award stands at zero, suggesting that the contract may operate on an order-based fulfillment method—typical for IDV contracts. This setup grants the flexibility to activate and fund orders as needed over the contract period, accommodating fluctuations in demand. While the total subaward amount remains undisclosed, the documentation specifies that the small business competitive implications are absent, aligning with the predetermined lack of small business set-asides. Also, the multiple awards under this framework contract demonstrate the government's strategic approach to diversifying supply risks and ensuring consistent pharmaceutical supply chains. The contract is meticulously administered by the Department of Veterans Affairs, particularly through the National Acquisition Center's Federal Supply Schedule office, highlighting their central role in securing the healthcare needs of veterans. The contract's structure, which avoids consolidation, facilitates tailored procurements, ensuring that precise and relevant needs are efficiently addressed without bundling products or services unnecessarily. Addressing the transactions associated with this award, eight modifications (Mods) have been recorded, reflecting updates and necessary administrative adjustments to the contract. These modifications, executed over the contract's lifecycle, ensure that both parties—VA and Dermavant Sciences Inc.—adhere to changing conditions, ensuring continued compliance with government procurement standards. Each transaction's repeated zero transaction amount further emphasizes the IDV's flexible operation, allowing the VA to obligate funds only upon individual task or delivery order approvals. This approach aids in budget management and aligns with governmental fiscal prudency mandates, maximizing taxpayer value. In conclusion, the contract between the Department of Veterans Affairs and Dermavant Sciences Inc. represents a strategic endeavor to meet the healthcare demands of veterans through the efficient procurement of vital pharmaceuticals. By aligning regulatory frameworks, competitive procurement strategies, and sophisticated contract structures, the government effectively leverages private sector capabilities to maintain and enhance its veterans' healthcare services. As the contract moves forward, monitoring its execution will continue spotlighting the endeavors to optimize healthcare delivery within the private-public partnership that defines this agreement.